What was Becton Dickinson's revenue and net income performance for the reported quarter?

For the three months ended March 31, 2004, Becton Dickinson reported revenues of $1,270.5 million, a 12.0% increase year-over-year. Net income was $165.2 million, or $0.62 per diluted share, compared to $142.0 million, or $0.54 per diluted share, in the same period of the prior year.

How did the different business segments perform in terms of revenue?

The Medical segment saw a 13.4% increase in revenue to $682.6 million. The Diagnostics segment's revenue grew 7.3% to $382.9 million. The Biosciences segment experienced the strongest growth, with revenues up 16.9% to $205.0 million.

What is the company's outlook on its financial condition and resources?

The company's balance sheet remains strong, with net cash provided by operating activities at $527.7 million for the first six months of fiscal 2004. The debt-to-capitalization ratio was reduced to 26.8%. Management is confident in its ability to generate cash flow and access financing for future growth.

Were there any significant charges or unusual items impacting the financial results?

Yes, in the prior quarter (ended December 31, 2003), the company recorded a pre-tax charge of $45.0 million related to its blood glucose monitoring products, which included a voluntary product recall and inventory write-offs. This charge impacted the current period's comparative results, though the company also noted a favorable tax rate impact for fiscal year 2004 due to these charges.

BDX 10-Q Quarterly Report Q2 FY2004 — Revenue, Net Income, EPS

Summary

Becton Dickinson & Co. (BDX) reported strong financial results for the second quarter and first half of fiscal year 2004, demonstrating solid revenue growth and improved profitability. The company's strategic focus on high-benefit products, operating effectiveness, and organizational capabilities is driving performance across its three key segments: Medical, Diagnostics, and Biosciences. Revenue increased by 12% year-over-year for the quarter, reaching $1.27 billion, with international sales showing particular strength, favorably impacted by foreign currency translation. The company also reported a strengthened balance sheet, with a reduced debt-to-capitalization ratio. Key financial highlights include net income of $165.16 million for the quarter and $290.56 million for the six months, leading to diluted earnings per share of $0.62 and $1.10, respectively. These results reflect effective cost management and growth in higher-margin products. While facing some challenges like inventory write-offs related to blood glucose monitoring products, the company's overall performance indicates robust operational execution and a positive outlook for continued growth.

Key Highlights

1Total revenues for the second quarter of fiscal year 2004 increased by 12% to $1.27 billion compared to the prior year period.
2Net income for the quarter was $165.16 million, resulting in diluted earnings per share of $0.62, up from $0.54 in the prior year.
3The Medical segment reported a 13% revenue increase year-over-year, driven by growth in prefillable drug delivery devices and diabetes-related products.
4The Biosciences segment showed strong revenue growth of 17% for the quarter, attributed to the BD FACSAria cell sorter and flow cytometry reagents.
5The company's debt-to-capitalization ratio improved to 26.8% as of March 31, 2004, down from 30.4% at September 30, 2003.
6Net cash provided by operating activities for the first six months of fiscal 2004 was $527.7 million.
7A pre-tax charge of $45.02 million was recorded in the previous quarter related to blood glucose monitoring products, including a product recall and inventory write-off.

BECTON DICKINSON & CO Quarterly Report for Q2 Ended Mar 31, 2004

Summary

Key Highlights

Frequently Asked Questions